According to the Interim Measures for the Administration of Medication in Basic Medical Insurance and other relevant documents, combined with the focus of the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog Management, the National Medical Insurance Administration has studied and drafted the "2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog Adjustment Work Plan (Draft for Comments)" and the "2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog Adjustment Application Guidelines (Draft for Comments)", including the scope and relevant work procedures of the 2024 drug catalog adjustment, and publicly solicited opinions from the society. According to the Work Plan (Draft for Comments), taking into account the functional orientation of basic medical insurance and industrial injury insurance, the clinical needs of drugs, and the affordability of funds, in 2024, the drug catalog will be adjusted. Western drugs and traditional Chinese patent medicines and simple preparations off the list will be subject to the provisions of Articles 7 and 8 of the Interim Measures for the Administration of Medication under Basic Medical Insurance, and drugs off the list that meet one of the following conditions can apply for the adjustment of the drug catalog in 2024: new generic drugs approved by the State Food and Drug Administration from January 1, 2019 (including, the same below) to June 30, 2024. During the period from January 1, 2019 to June 30, 2024, drugs that have undergone significant changes in indications or functional indications with the approval of the national drug regulatory department, and have obtained drug approval documents for this change. Drugs included in the National Essential Medicines Catalogue (2018 Edition). Drugs included in the list of encouraged generic drugs or encouraged research and development to apply for the list of children's drugs, and approved for marketing by the national drug regulatory department before June 30, 2024. Rare disease treatment drugs approved for marketing by the national drug regulatory department before June 30, 2024. In addition, renewal and bidding will follow last year's rules and will be announced together with the finalized work plan and related documents. (Lai Xin She)